Search
Selected Filter
Displaying 21–30 of 271 research results
-
ProQR’s Phase 2/3 Clinical Trial for LCA10 RNA Therapy Doesn’t Meet Endpoints
Eye On the Cure Research NewsThe emerging treatment had shown encouraging results in a Phase ½ clinical trial
-
AGTC Plans Further Clinical Development of Achromatopsia (CNGB3) Gene Therapy
Eye On the Cure Research NewsInterim results for pediatric patients with CNGB3 mutations were encouraging
-
Genentech-Roche Receives FDA Approval for Vabysmo for Treatment of Wet AMD and DME
Eye On the Cure Research NewsThis new treatment can reduce the frequency of injections into the eye
-
Kriya Therapeutics Licenses Emerging Foundation-Funded Dry AMD Gene Therapy
Eye On the Cure Research NewsThe Foundation Fighting Blindness is funding Bärb Rohrer, PhD, Medical University of South Carolina, to evaluate safety and efficacy of the gene therapy in a large animal model
-
ReNeuron Not Continuing Clinical Development of Cell-Based Therapy for RP
Eye On the Cure Research NewsCompany seeks to out-license its retinal progenitor therapy to a partner
-
Eye On the Cure Research News
Survey results will inform therapy developers and the agenda for a Patient-Focused Drug Development meeting with Food and Drug Administration representatives.
-
Eye On the Cure Research News
The company is currently developing programs for Stargardt disease (ABCA4), Usher syndrome, RP25 (EYS), and RP1.
-
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
Eye On the Cure Research NewsThe Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
-
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
Eye On the Cure Research NewsThe clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
-
Geographic Atrophy: The Advanced Form of Dry AMD
Science EducationGeographic atrophy causes significant central vision loss and remains an unmet medical need.
.png)
.png)
.png)
